Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration

Sudhir Agrawal, Xueshu Zhang, Zhihong Lu, Hui Zhao, Jeffrey M. Tamburin, Jieming Van, Hongying Cai, Robert B Diasio, Ivan Habus, Zhiwei Jiang, Radhakrishnan P. Iyer, Dong Yu, Ruiwen Zhang

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

In vivo stability and oral bioavailability of an oligodeoxynucleotide phosphorothioate containing segments of 2′-O-methyloligoribonucleotide phosphorothioates at both the 3′- and 5′-ends (hybrid oligonucleotide) were studied. A 25-mer 35S-labeled hybrid oligonucleotide was administered to rats by gavage at a dose of 50 mg/kg body weight. HPLC analysis revealed that this hybrid oligonucleotide was stable in the gastrointestinal tract for up to 6 hr following oral administration. Radioactivity associated with the hybrid oligonucleotide was detectable in portal venous plasma, systemic plasma, various tissues, and urine. Intact hybrid oligonucleotide was detected, by HPLC analysis, in portal venous plasma, systemic plasma, and various tissues. The majority of the radioactivity in urine was associated with degradative products with lower molecular weights, but the intact form was also detected. In summary, the hybrid oligonucleotide was absorbed intact through the gastrointestinal tract, indicating the possibility of oral administration of oligonucleotides, a finding that may be important in the development of antisense oligonucleotides as therapeutic agents.

Original languageEnglish (US)
Pages (from-to)571-576
Number of pages6
JournalBiochemical Pharmacology
Volume50
Issue number4
DOIs
StatePublished - Aug 8 1995
Externally publishedYes

Fingerprint

Antisense Oligonucleotides
Tissue Distribution
Oligonucleotides
Oral Administration
Rats
Tissue
Plasmas
Radioactivity
Gastrointestinal Tract
High Pressure Liquid Chromatography
Urine
Oligodeoxyribonucleotides
Biological Availability
Molecular Weight
Molecular weight
Body Weight

Keywords

  • antisense oligonucleotides
  • HIV
  • oral bioavailability

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. / Agrawal, Sudhir; Zhang, Xueshu; Lu, Zhihong; Zhao, Hui; Tamburin, Jeffrey M.; Van, Jieming; Cai, Hongying; Diasio, Robert B; Habus, Ivan; Jiang, Zhiwei; Iyer, Radhakrishnan P.; Yu, Dong; Zhang, Ruiwen.

In: Biochemical Pharmacology, Vol. 50, No. 4, 08.08.1995, p. 571-576.

Research output: Contribution to journalArticle

Agrawal, S, Zhang, X, Lu, Z, Zhao, H, Tamburin, JM, Van, J, Cai, H, Diasio, RB, Habus, I, Jiang, Z, Iyer, RP, Yu, D & Zhang, R 1995, 'Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration', Biochemical Pharmacology, vol. 50, no. 4, pp. 571-576. https://doi.org/10.1016/0006-2952(95)00160-2
Agrawal, Sudhir ; Zhang, Xueshu ; Lu, Zhihong ; Zhao, Hui ; Tamburin, Jeffrey M. ; Van, Jieming ; Cai, Hongying ; Diasio, Robert B ; Habus, Ivan ; Jiang, Zhiwei ; Iyer, Radhakrishnan P. ; Yu, Dong ; Zhang, Ruiwen. / Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. In: Biochemical Pharmacology. 1995 ; Vol. 50, No. 4. pp. 571-576.
@article{6669760ad59147c4bbe619dac6ed7e88,
title = "Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration",
abstract = "In vivo stability and oral bioavailability of an oligodeoxynucleotide phosphorothioate containing segments of 2′-O-methyloligoribonucleotide phosphorothioates at both the 3′- and 5′-ends (hybrid oligonucleotide) were studied. A 25-mer 35S-labeled hybrid oligonucleotide was administered to rats by gavage at a dose of 50 mg/kg body weight. HPLC analysis revealed that this hybrid oligonucleotide was stable in the gastrointestinal tract for up to 6 hr following oral administration. Radioactivity associated with the hybrid oligonucleotide was detectable in portal venous plasma, systemic plasma, various tissues, and urine. Intact hybrid oligonucleotide was detected, by HPLC analysis, in portal venous plasma, systemic plasma, and various tissues. The majority of the radioactivity in urine was associated with degradative products with lower molecular weights, but the intact form was also detected. In summary, the hybrid oligonucleotide was absorbed intact through the gastrointestinal tract, indicating the possibility of oral administration of oligonucleotides, a finding that may be important in the development of antisense oligonucleotides as therapeutic agents.",
keywords = "antisense oligonucleotides, HIV, oral bioavailability",
author = "Sudhir Agrawal and Xueshu Zhang and Zhihong Lu and Hui Zhao and Tamburin, {Jeffrey M.} and Jieming Van and Hongying Cai and Diasio, {Robert B} and Ivan Habus and Zhiwei Jiang and Iyer, {Radhakrishnan P.} and Dong Yu and Ruiwen Zhang",
year = "1995",
month = "8",
day = "8",
doi = "10.1016/0006-2952(95)00160-2",
language = "English (US)",
volume = "50",
pages = "571--576",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration

AU - Agrawal, Sudhir

AU - Zhang, Xueshu

AU - Lu, Zhihong

AU - Zhao, Hui

AU - Tamburin, Jeffrey M.

AU - Van, Jieming

AU - Cai, Hongying

AU - Diasio, Robert B

AU - Habus, Ivan

AU - Jiang, Zhiwei

AU - Iyer, Radhakrishnan P.

AU - Yu, Dong

AU - Zhang, Ruiwen

PY - 1995/8/8

Y1 - 1995/8/8

N2 - In vivo stability and oral bioavailability of an oligodeoxynucleotide phosphorothioate containing segments of 2′-O-methyloligoribonucleotide phosphorothioates at both the 3′- and 5′-ends (hybrid oligonucleotide) were studied. A 25-mer 35S-labeled hybrid oligonucleotide was administered to rats by gavage at a dose of 50 mg/kg body weight. HPLC analysis revealed that this hybrid oligonucleotide was stable in the gastrointestinal tract for up to 6 hr following oral administration. Radioactivity associated with the hybrid oligonucleotide was detectable in portal venous plasma, systemic plasma, various tissues, and urine. Intact hybrid oligonucleotide was detected, by HPLC analysis, in portal venous plasma, systemic plasma, and various tissues. The majority of the radioactivity in urine was associated with degradative products with lower molecular weights, but the intact form was also detected. In summary, the hybrid oligonucleotide was absorbed intact through the gastrointestinal tract, indicating the possibility of oral administration of oligonucleotides, a finding that may be important in the development of antisense oligonucleotides as therapeutic agents.

AB - In vivo stability and oral bioavailability of an oligodeoxynucleotide phosphorothioate containing segments of 2′-O-methyloligoribonucleotide phosphorothioates at both the 3′- and 5′-ends (hybrid oligonucleotide) were studied. A 25-mer 35S-labeled hybrid oligonucleotide was administered to rats by gavage at a dose of 50 mg/kg body weight. HPLC analysis revealed that this hybrid oligonucleotide was stable in the gastrointestinal tract for up to 6 hr following oral administration. Radioactivity associated with the hybrid oligonucleotide was detectable in portal venous plasma, systemic plasma, various tissues, and urine. Intact hybrid oligonucleotide was detected, by HPLC analysis, in portal venous plasma, systemic plasma, and various tissues. The majority of the radioactivity in urine was associated with degradative products with lower molecular weights, but the intact form was also detected. In summary, the hybrid oligonucleotide was absorbed intact through the gastrointestinal tract, indicating the possibility of oral administration of oligonucleotides, a finding that may be important in the development of antisense oligonucleotides as therapeutic agents.

KW - antisense oligonucleotides

KW - HIV

KW - oral bioavailability

UR - http://www.scopus.com/inward/record.url?scp=0029100397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029100397&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(95)00160-2

DO - 10.1016/0006-2952(95)00160-2

M3 - Article

C2 - 7646565

AN - SCOPUS:0029100397

VL - 50

SP - 571

EP - 576

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 4

ER -